Nimodipine(Synonyms: 尼莫地平; BAY-e 9736)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Nimodipine (Synonyms: 尼莫地平; BAY-e 9736) 纯度: 99.42%

Nimodipine (BAY-e 9736) 是一种具有口服活性，耐受性良好的光敏二氢吡啶钙拮抗剂。Nimodipine 可以用于脑血管疾病的研究。

Nimodipine(Synonyms: 尼莫地平; BAY-e 9736)

Nimodipine Chemical Structure

CAS No. : 66085-59-4

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥500 In-stock
100 mg ￥400 In-stock
500 mg ￥800 In-stock
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

Nimodipine 相关产品

•相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Membrane Transporter/Ion Channel Compound Library
  • Neuronal Signaling Compound Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • CNS-Penetrant Compound Library
  • Autophagy Compound Library
  • Drug Repurposing Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • NMPA-Approved Drug Library
  • Orally Active Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Neuroprotective Compound Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Rare Diseases Drug Library

生物活性

Nimodipine (BAY-e 9736) is an orally active, well-tolerated and light-sensitive dihydropyridine calcium antagonist. Nimodipine can be used for the research of cerebrovascular disorders[1].

IC50 & Target

dihydropyridine calcium[1]
体外研究
(In Vitro)

Nimodipine (1.5~150 μg/ml; 15 minutes; B16a and W256 cells) results in a dose-dependent inhibition of B16a and W256 tumor-cell-induced platelet aggregation. Nimodipine is also inhibitory in a homologous system[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Nimodipine (0.2 µg/µl, intrathecal administration) prevents subarachnoid hemorrhage-associated cerebral vasospasm by prophylactic continuous intrathecal administration[2].
Nimodipine(0.1~80 mg/kg; p.o.) results in a significant dose-dependent inhibition of spontaneous metastasis[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: New Zealand white rabbits[2]
Dosage: 0.2 µg/µl
Administration: Intrathecal administration
Result: Prevented subarachnoid hemorrhage-associated cerebral vasospasm by prophylactic continuous intrathecal administration.

Clinical Trial

分子量

418.44

Formula

C21H26N2O7
CAS 号

66085-59-4
中文名称

尼莫地平；硝苯比酯；硝苯甲氧乙基异丙啶
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (238.98 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.3898 mL 11.9491 mL 23.8983 mL
5 mM 0.4780 mL 2.3898 mL 4.7797 mL
10 mM 0.2390 mL 1.1949 mL 2.3898 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (5.97 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.97 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (5.97 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.97 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Langley, M.S., et al. Nimodipine. Drugs 37, 669–699 (1989).

    [2]. Marbacher S, et al. Prevention of delayed cerebral vasospasm by continuous intrathecal infusion of glyceroltrinitrate and nimodipine in the rabbit model in vivo. Intensive Care Med. 2008;34(5):932-938.

    [3]. Honn KV, et al. Inhibition of tumor cell-platelet interactions and tumor metastasis by the calcium channel blocker, nimodipine. Clin Exp Metastasis. 1984;2(1):61-72.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务